Literature DB >> 19484165

Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia.

M Saito1, K Marumo, S Soshi, Y Kida, C Ushiku, A Shinohara.   

Abstract

UNLABELLED: We demonstrate a reduction in enzymatic divalent immature and trivalent pyridinium cross-links and an increase in the nonenzymatic cross-link, pentosidine (Pen), in rabbits with methionine (Met)-induced hyperhomocysteinemia. Such detrimental cross-link formation in bone was ameliorated by raloxifene (RLX) treatment.
INTRODUCTION: Collagen cross-links are determinants of bone quality. Homocysteine (Hcys) interferes with collagen cross-linking. Because RLX is thought to ameliorate bone quality, we investigated whether RLX ameliorated hyperhomocysteinemia-induced cross-link abnormalities using a Met-rich diet rabbit model.
METHODS: We divided New Zealand white rabbits into six groups (n = 6 per group): baseline control, sham operation, sham + 1% Met diet, ovariectomy (OVX), 1% Met diet + OVX, OVX + RLX (10 mg/kg/day), and 1% Met diet + OVX + RLX. RLX was administered for 16 weeks. We measured the amount of enzymatic immature and mature pyridinium cross-links and the nonenzymatic cross-link, Pen, and correlated the cross-link content to bone strength.
RESULTS: Hcys levels were significantly higher in the Met diet groups than in the normal diet groups. Met-fed rabbits with or without OVX showed a significant reduction of enzymatic cross-links, whereas an increase in Pen was observed in Met-fed rabbits with OVX. The cross-link content of the RLX-treated Met-fed rabbits with OVX was restored to similar levels as the sham group, accompanied by an improvement of bone strength.
CONCLUSION: These results demonstrate that hyperhomocysteinemia reduced bone strength via a reduction of enzymatic cross-links and an increase of nonenzymatic cross-links. RLX may ameliorate hyperhomocysteinemia-induced detrimental cross-linking in rabbits with OVX and may improve bone strength via the amelioration of collagen cross-links.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484165     DOI: 10.1007/s00198-009-0980-4

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  59 in total

1.  The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial.

Authors:  B W Walsh; S Paul; R A Wild; R A Dean; R P Tracy; D A Cox; P W Anderson
Journal:  J Clin Endocrinol Metab       Date:  2000-01       Impact factor: 5.958

Review 2.  The role of the collagen matrix in skeletal fragility.

Authors:  Deepak Vashishth
Journal:  Curr Osteoporos Rep       Date:  2007-06       Impact factor: 5.096

3.  Bone matrix quality and plasma homocysteine levels.

Authors:  S Blouin; H W Thaler; C Korninger; R Schmid; J G Hofstaetter; R Zoehrer; R Phipps; K Klaushofer; P Roschger; E P Paschalis
Journal:  Bone       Date:  2009-01-09       Impact factor: 4.398

4.  Regional distinctions in cortical bone mineral density measured by pQCT can predict alterations in material property at the tibial diaphysis of the Cynomolgus monkey.

Authors:  Kiichi Nonaka; Satoshi Fukuda; Kazuhiro Aoki; Takashi Yoshida; Keiichi Ohya
Journal:  Bone       Date:  2005-10-05       Impact factor: 4.398

5.  Decreased collagen organization and content are associated with reduced strength of demineralized and intact bone in the SAMP6 mouse.

Authors:  Matthew J Silva; Michael D Brodt; Brigitte Wopenka; Stavros Thomopoulos; Derek Williams; Maurice H M Wassen; Mike Ko; Nozomu Kusano; Ruud A Bank
Journal:  J Bone Miner Res       Date:  2005-09-19       Impact factor: 6.741

6.  Effect of hyper- and microgravity on collagen post-translational controls of MC3T3-E1 osteoblasts.

Authors:  Mitsuru Saito; Shigeru Soshi; Katsuyuki Fujii
Journal:  J Bone Miner Res       Date:  2003-09       Impact factor: 6.741

7.  Age-related changes in the collagen network and toughness of bone.

Authors:  X Wang; X Shen; X Li; C Mauli Agrawal
Journal:  Bone       Date:  2002-07       Impact factor: 4.398

8.  Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses.

Authors:  P D Delmas; Zhengqing Li; Cyrus Cooper
Journal:  J Bone Miner Res       Date:  2003-12-16       Impact factor: 6.741

9.  Pre- and post-translational regulation of lysyl oxidase by transforming growth factor-beta 1 in osteoblastic MC3T3-E1 cells.

Authors:  E J Feres-Filho; Y J Choi; X Han; T E Takala; P C Trackman
Journal:  J Biol Chem       Date:  1995-12-22       Impact factor: 5.157

10.  Collagen maturity, glycation induced-pentosidine, and mineralization are increased following 3-year treatment with incadronate in dogs.

Authors:  M Saito; S Mori; T Mashiba; S Komatsubara; K Marumo
Journal:  Osteoporos Int       Date:  2008-03-29       Impact factor: 5.071

View more
  30 in total

1.  Urinary pentosidine and plasma homocysteine levels at baseline predict future fractures in osteoporosis patients under bisphosphonate treatment.

Authors:  Masataka Shiraki; Tatsuhiko Kuroda; Yumiko Shiraki; Shiro Tanaka; Tsuyoshi Higuchi; Mitsuru Saito
Journal:  J Bone Miner Metab       Date:  2010-05-11       Impact factor: 2.626

2.  Pentosidine concentration is associated with degenerative lumbar scoliosis in older women: preliminary results.

Authors:  Yawara Eguchi; Toru Toyoguchi; Kazuhide Inage; Kazuki Fujimoto; Sumihisa Orita; Kazuyo Yamauchi; Miyako Suzuki; Hirohito Kanamoto; Koki Abe; Masaki Norimoto; Tomotaka Umimura; Masao Koda; Takeo Furuya; Yasuchika Aoki; Kazuhisa Takahashi; Seiji Ohtori
Journal:  Eur Spine J       Date:  2017-11-10       Impact factor: 3.134

3.  Characteristics of bone turnover, bone mass and bone strength in Spontaneously Diabetic Torii-Lepr fa rats.

Authors:  Shuichi Kimura; Tomohiko Sasase; Takeshi Ohta; Eimei Sato; Mutsuyoshi Matsushita
Journal:  J Bone Miner Metab       Date:  2011-10-27       Impact factor: 2.626

4.  Effects of raloxifene and alendronate on non-enzymatic collagen cross-links and bone strength in ovariectomized rabbits in sequential treatments after daily human parathyroid hormone (1-34) administration.

Authors:  S Kimura; M Saito; Y Kida; A Seki; Y Isaka; K Marumo
Journal:  Osteoporos Int       Date:  2016-10-29       Impact factor: 4.507

Review 5.  The Effects of Homocysteine on the Skeleton.

Authors:  Mitsuru Saito; Keishi Marumo
Journal:  Curr Osteoporos Rep       Date:  2018-10       Impact factor: 5.096

Review 6.  Mitochondrial epigenetics in bone remodeling during hyperhomocysteinemia.

Authors:  Anuradha Kalani; Pradip K Kamat; Michael J Voor; Suresh C Tyagi; Neetu Tyagi
Journal:  Mol Cell Biochem       Date:  2014-06-18       Impact factor: 3.396

Review 7.  Collagen cross-links as a determinant of bone quality: a possible explanation for bone fragility in aging, osteoporosis, and diabetes mellitus.

Authors:  M Saito; K Marumo
Journal:  Osteoporos Int       Date:  2010-02       Impact factor: 4.507

8.  Effects of raloxifene on lipid and bone metabolism in postmenopausal women with type 2 diabetes.

Authors:  Hiroko Mori; Yosuke Okada; Hirofumi Kishikawa; Nobuo Inokuchi; Hidekatsu Sugimoto; Yoshiya Tanaka
Journal:  J Bone Miner Metab       Date:  2012-08-07       Impact factor: 2.626

Review 9.  Diabetes, collagen, and bone quality.

Authors:  Mitsuru Saito; Yoshikuni Kida; Soki Kato; Keishi Marumo
Journal:  Curr Osteoporos Rep       Date:  2014-06       Impact factor: 5.096

Review 10.  Collagen modifications in postmenopausal osteoporosis: advanced glycation endproducts may affect bone volume, structure and quality.

Authors:  Thomas L Willett; Julia Pasquale; Marc D Grynpas
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.